Exact Sciences Announces Aetna Medicare Advantage to Cover Cologuard®

exs-er-BlogHeader-Aetna-01

MADISON, Wis.—(BUSINESS WIRE)— Exact Sciences Corp. (NASDAQ:EXAS) today announced that Aetna, one of the country's leading health plans, will cover Cologuard under its Medicare Advantage plan, reaching 967,000 members across the country. The three year agreement will go into effect on April 1, 2015.

Cologuard is the first and only FDA approved noninvasive stool-based DNA (sDNA) screening test for colon cancer. The test will be available to Aetna's Medicare Advantage members through their physician without a co-payment or co-insurance.

"We look forward to working with Aetna to provide their members with a new option for colon cancer screening. Colon cancer is most treatable when caught early, underscoring the importance of routine screening," said Kevin Conroy, Chairman and CEO of Exact Sciences.

Cologuard offers people 50 years and older who are at average risk for colorectal cancer an easy to use screening test which they can do in the privacy of their own home. Unlike many other screening options, Cologuard does not require medication, dietary restrictions or bowel preparation prior to taking the test. It is the first noninvasive screening test for colorectal cancer that analyzes both sDNA and blood biomarkers to detect cancer and precancer. Cologuard is available by prescription only.

For more information, visit www.CologuardTest.com or call 1-844-870-8870.

About Exact Sciences Corp.

Exact Sciences Corp. (NASDAQ:EXAS) is a molecular diagnostics company focused on the early detection and prevention of colorectal cancer. The company has exclusive intellectual property protecting its noninvasive, molecular screening technology for the detection of colorectal cancer. Cologuard is included in the colorectal cancer screening guidelines of the American Cancer Society and stool DNA is included in the U.S. Multi-Society Task Force on Colorectal Cancer. For more information, follow us on Twitter @ExactSciences or find us on Facebook.

Certain statements made in this news release contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended that are intended to be covered by the "safe harbor" created by those sections. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "could," "seek," "intend," "plan," "estimate," "anticipate" or other comparable terms. Forward-looking statements in this news release may address the following subjects among others: statements regarding the sufficiency of our capital resources, our ability to secure favorable reimbursement rates from Medicare and other third-party payors, timing of our launch of a commercial product, our estimates of the available market size and our potential penetration, expected research and development expenses, expected general and administrative expenses and our expectations concerning our business strategy. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our most recently filed Annual Report on Form 10-K and our subsequently filed Quarterly Reports on Form 10-Q. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

Exact Sciences
Cara Tucker, 614-302-5622
ctucker@exactsciences.com
or
MSLGROUP
Jayme Maniatis and Rachel Gross, 781-684-0770
exactsciences@mslgroup.com

Source: Exact Sciences Corp.

News Provided by Acquire Media

Topics: Exact Sciences News